Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BRTX
stocks logo

BRTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
150.00K
+246.42%
-0.375
+87.5%
575.00K
+2200%
-0.250
-60.94%
600.00K
+97.82%
-0.260
-13.33%
Estimates Revision
The market is revising Downward the revenue expectations for BioRestorative Therapies, Inc. (BRTX) for FY2025, with the revenue forecasts being adjusted by -9.26% over the past three months. During the same period, the stock price has changed by -30.62%.
Revenue Estimates for FY2025
Revise Downward
down Image
-9.26%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.87%
In Past 3 Month
Stock Price
Go Down
down Image
-30.62%
In Past 3 Month
Wall Street analysts forecast BRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRTX is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast BRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRTX is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.110
sliders
Low
8.00
Averages
8.00
High
8.00
Current: 1.110
sliders
Low
8.00
Averages
8.00
High
8.00
no data image
No Data

Valuation Metrics

The current forward P/E ratio for BioRestorative Therapies Inc (BRTX.O) is -1.01, compared to its 5-year average forward P/E of -1.82. For a more detailed relative valuation and DCF analysis to assess BioRestorative Therapies Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.82
Current PE
-1.01
Overvalued PE
0.38
Undervalued PE
-4.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
179.30
Current PS
0.00
Overvalued PS
414.31
Undervalued PS
-55.71
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

BRTX News & Events

Events Timeline

(ET)
2025-11-17
07:10:23
BioRestorative Therapies Receives Type B Meeting Approval for BRTX-100 BLA Pathway
select
2025-10-27 (ET)
2025-10-27
07:34:54
BioRestorative Receives Notice of Allowance from JPO for ThermoStem Platform
select
2025-10-22 (ET)
2025-10-22
09:37:09
BioRestorative Therapies Appoints Crystal Romano as Head of Global Commercial Operations
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-18NASDAQ.COM
NOTV and APLT Top After-Hours Biotech Gains; ALMS, TELA, CORT, and BRTX Also Show Progress

  • Biotech Gains in After-Hours Trading: Several small-cap biotech companies saw significant stock price increases in after-hours trading, driven by earnings updates and regulatory news.

  • Inotiv, Inc. Performance: Inotiv, Inc. experienced a 36.61% surge to $0.94 after announcing preliminary Q4 and full-year 2025 revenue projections, recovering from a prior decline.

  • Applied Therapeutics and Alumis Updates: Applied Therapeutics rose 16.89% following a positive earnings report, while Alumis advanced 7.09% despite a wider Q3 net loss, supported by collaboration income.

  • Regulatory Developments for BioRestorative: BioRestorative Therapies gained 8.06% after announcing a meeting with the FDA to discuss a potential accelerated pathway for its treatment of chronic lumbar disc disease.

[object Object]
Preview
9.5
11-14NASDAQ.COM
Transcript of BioRestorative (BRTX) Earnings Call
  • Author's Perspective: The views and opinions presented are solely those of the author.
  • No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
[object Object]
Preview
9.5
11-13NASDAQ.COM
Biorestorative Therapies, Inc. (BRTX) Announces Q3 Loss and Falls Short of Revenue Projections

  • Quarterly Performance: Biorestorative Therapies, Inc. (BRTX) reported a quarterly loss of $0.38 per share, matching expectations but worsening from a loss of $0.13 per share a year ago, with revenues significantly missing estimates at $0.01 million.

  • Stock Outlook: The company's stock has underperformed, losing about 1.4% this year compared to the S&P 500's 16.4% gain, and currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.

  • Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.28 on $0.5 million in revenues, while the current fiscal year estimate is -$1.55 on $1.23 million in revenues, reflecting mixed trends in earnings estimate revisions.

  • Industry Context: Biorestorative operates within the Medical - Biomedical and Genetics industry, which ranks in the top 34% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is BioRestorative Therapies Inc (BRTX) stock price today?

The current price of BRTX is 1.11 USD — it has increased 2.78 % in the last trading day.

arrow icon

What is BioRestorative Therapies Inc (BRTX)'s business?

BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.

arrow icon

What is the price predicton of BRTX Stock?

Wall Street analysts forecast BRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRTX is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is BioRestorative Therapies Inc (BRTX)'s revenue for the last quarter?

BioRestorative Therapies Inc revenue for the last quarter amounts to 11.80K USD, decreased -94.95 % YoY.

arrow icon

What is BioRestorative Therapies Inc (BRTX)'s earnings per share (EPS) for the last quarter?

BioRestorative Therapies Inc. EPS for the last quarter amounts to -0.33 USD, increased 153.85 % YoY.

arrow icon

What changes have occurred in the market's expectations for BioRestorative Therapies Inc (BRTX)'s fundamentals?

The market is revising Downward the revenue expectations for BioRestorative Therapies, Inc. (BRTX) for FY2025, with the revenue forecasts being adjusted by -9.26% over the past three months. During the same period, the stock price has changed by -30.62%.
arrow icon

How many employees does BioRestorative Therapies Inc (BRTX). have?

BioRestorative Therapies Inc (BRTX) has 11 emplpoyees as of December 05 2025.

arrow icon

What is BioRestorative Therapies Inc (BRTX) market cap?

Today BRTX has the market capitalization of 9.85M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free